LifeMD (LFMD) Stock Forecast & Price Target

LifeMD is supported by a differentiated direct-to-patient model that combines virtual care, pharmacy fulfillment, and AI-enabled clinical operations, creating a convenient alternative in a system where wait times can exceed 30 days and doctor shortages persist. Growth is being driven by high-demand categories, with weight management subscribers at about 108,000 at end-2Q26, total active subscribers up 20% year over year to about 356,000, and women’s health patient growth rising 134% sequentially with a $3M-$5M quarterly revenue run rate expected in 4Q26. Its outlook is further strengthened by the AT&T collaboration reaching 29 million customers in 11 states, more than 100 million eligible nationwide, and by expanding coverage across roughly 175 million covered lives, which can improve customer acquisition, retention, and future profitability.

LifeMD is under pressure because 2Q26 revenue of $47.3M declined 4% year over year and missed expectations, while adjusted EBITDA of ($3.5M) and a net loss of $7.9M showed that profitability remains weak. Management also cut FY2026 revenue guidance to $205.5M-$212.5M from $220M-$230M and adjusted EBITDA to ($6M)-break-even, reflecting underestimated costs tied to the shift toward branded GLP-1s, a new pharma collaboration, and scaling broader capabilities. Although subscribers rose to about 356,000 and weight management subscribers reached 108,000, slower new-member growth, high CAC earlier in the quarter, and intensifying competition suggest the business is still struggling to convert operational expansion into consistent earnings.